Top FDA Compliance Official Notes 'Revival' Of Data Integrity Fraud
Executive Summary
A top FDA compliance official warns the generic drug industry of a “revival” of data integrity fraud as a number of brand-name drugs go off patent and companies rush to be the first to file.